Cargando…

Should ACE Inhibitors and Angiotensin Receptor Blockers Be Withdrawn in the Current Setting of COVID-19 Infection?

Detalles Bibliográficos
Autor principal:	Manga, Pravin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wits University Press 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187740/ http://dx.doi.org/10.18772/26180197.2020.v2nSIa4

Ejemplares similares

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients
por: Daoud, Ahmed, et al.
Publicado: (2021)

Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension
por: Tian, Ci, et al.
Publicado: (2021)

Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes
por: Chae, Young Kwang, et al.
Publicado: (2013)

COVID-19 and ACE -inhibitors and angiotensin receptor blockers-: The need to differentiate between early infection and acute lung injury
por: GonzÃ¡lez-Rayas, JosÃ© Manuel, et al.
Publicado: (2020)

ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19
por: Wang, Yueying, et al.
Publicado: (2020)

Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
por: Javanmard, Shaghayegh Haghjooy, et al.
Publicado: (2020)

Comparative effectiveness of ACE inhibitors and angiotensin receptor blockers in patients with prior myocardial infarction
por: Ko, Dennis, et al.
Publicado: (2019)

Reply: ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19
por: Amat-Santos, Ignacio J., et al.
Publicado: (2020)

Effect of ACE inhibitors and angiotensin receptor blockers on in-hospital mortality and length of stay in hospitalized COVID-19 patients
por: LaClair, Heather J., et al.
Publicado: (2021)

SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19?
por: Kuster, Gabriela M, et al.
Publicado: (2020)

Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?
por: Trifirò, Gianluca, et al.
Publicado: (2020)

Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) Are Protective Against ICU Admission and Mortality for Patients With COVID-19 Disease
por: ElAbd, Rawan, et al.
Publicado: (2021)

Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19
por: Li, Xiao-Long, et al.
Publicado: (2021)

Mechanisms by which angiotensin-receptor blockers increase ACE2 levels
por: Ferrario, Carlos M., et al.
Publicado: (2020)

An epidemiological study exploring a possible impact of treatment with ACE inhibitors or angiotensin receptor blockers on ACE2 plasma concentrations
por: Wild, Philipp S., et al.
Publicado: (2020)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

ACE Inhibitor/Angiotensin Receptor Blocker Use Patterns in Advanced CKD and Risk of Kidney Failure and Death
por: Arora, Nayan, et al.
Publicado: (2020)

Angiotensin receptor blockers and COVID-19
por: Saavedra, Juan M.
Publicado: (2020)

Robust ACE2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is not increased by ACE inhibitors or angiotensin receptor blockers
por: Lee, Ivan T., et al.
Publicado: (2020)

Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people
por: Hippisley-Cox, Julia, et al.
Publicado: (2020)

RU28318, an Aldosterone Antagonist, in Combination with an ACE Inhibitor and Angiotensin Receptor Blocker Attenuates Cardiac Dysfunction in Diabetes
por: Benter, Ibrahim F., et al.
Publicado: (2013)

Associations between ACE-Inhibitors, Angiotensin Receptor Blockers, and Lean Body Mass in Community Dwelling Older Women
por: Bea, Jennifer W., et al.
Publicado: (2018)

A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors
por: Siragy, Helmy M
Publicado: (2011)

Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study
por: Parit, Rahul, et al.
Publicado: (2021)

Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
por: Wong, Martin C.S., et al.
Publicado: (2020)

The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients
por: Harky, Amer, et al.
Publicado: (2021)

Differential Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on COVID-19
por: Su, Lianjiu, et al.
Publicado: (2021)

COVID-19, Angiotensin Receptor Blockers, and the Brain
por: Saavedra, Juan M.
Publicado: (2020)

Severe intestinal malabsorption associated with ACE inhibitor or angiotensin receptor blocker treatment. An observational cohort study in Germany and Italy
por: Malfertheiner, Peter, et al.
Publicado: (2018)

Association of outpatient ACE inhibitors and angiotensin receptor blockers and outcomes of acute respiratory illness: a retrospective cohort study
por: Jeffery, Molly Moore, et al.
Publicado: (2021)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
por: Moore, Graham J., et al.
Publicado: (2021)

To do or not to do: Angiotensin converting enzyme inhibitors/angiotensin receptor blocker in COVID-19 elderly patients
por: Vura, Naga Venkata Rama Krishna, et al.
Publicado: (2021)

Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID‐19
por: Pan, Michael, et al.
Publicado: (2021)

Theoretical Assessment of Therapeutic Effects of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19
por: Khalili, Azadeh, et al.
Publicado: (2021)

Assessing the outcomes of prescribing angiotensin converting enzyme inhibitors and angiotensin receptor blockers for COVID-19 patients
por: Mekary, Wissam, et al.
Publicado: (2023)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

Comparative assessment of angiotensin receptor blockers in different clinical settings
por: Verdecchia, Paolo, et al.
Publicado: (2009)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
por: Ajmal, Adnan, et al.
Publicado: (2013)

Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide
por: Mamdani, Muhammad, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jleq5dtvb2ns351avahftmue5s